Patients and disease characteristics
| Characteristic . | Patients . | ||
|---|---|---|---|
| N . | Age (y) . | % of total . | |
| Sex | |||
| Female | 12 | 46.2 | |
| Male | 14 | 53.8 | |
| Age, median (range) | 60 (42-66) | ||
| Ig subtype | |||
| IgG | 12 | 46.2 | |
| IgA | 9 | 34.6 | |
| IgM | 0 | 0 | |
| IgE | 0 | 0 | |
| FLCs | 5 | 19.2 | |
| Nonsecretory | 0 | 0 | |
| ISS stage | |||
| I | 5 | 19.2 | |
| II | 8 | 30.8 | |
| III | 13 | 50.0 | |
| Response to HDM | |||
| Responders | 17 | 65.4 | |
| Nonresponders | 9 | 34.6 | |
| High-risk cytogenetics* | |||
| Responders | 6 | 35.3 | |
| Nonresponders | 4 | 44.4 | |
| Characteristic . | Patients . | ||
|---|---|---|---|
| N . | Age (y) . | % of total . | |
| Sex | |||
| Female | 12 | 46.2 | |
| Male | 14 | 53.8 | |
| Age, median (range) | 60 (42-66) | ||
| Ig subtype | |||
| IgG | 12 | 46.2 | |
| IgA | 9 | 34.6 | |
| IgM | 0 | 0 | |
| IgE | 0 | 0 | |
| FLCs | 5 | 19.2 | |
| Nonsecretory | 0 | 0 | |
| ISS stage | |||
| I | 5 | 19.2 | |
| II | 8 | 30.8 | |
| III | 13 | 50.0 | |
| Response to HDM | |||
| Responders | 17 | 65.4 | |
| Nonresponders | 9 | 34.6 | |
| High-risk cytogenetics* | |||
| Responders | 6 | 35.3 | |
| Nonresponders | 4 | 44.4 | |
High-risk cytogenetics are defined as the presence of t(4;14), t(4;20), deletion 17p13, or 1q21 gain.